Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis

Area of Science:

• Cardiology
• Immunology
• Pathology

Background:

• Giant cell myocarditis (GCM) is a rare, aggressive cardiac disease with poor prognosis.
• Long-term outcomes for GCM patients surviving beyond one year without heart transplantation are not well-documented.

Purpose of the Study:

• To investigate the long-term outcomes and complication rates in patients with biopsy-proven GCM who survived for over one year without heart transplantation.
• To determine the incidence of GCM recurrence, death, transplantation, and other adverse events in this cohort.

Main Methods:

• Retrospective analysis of a multicenter GCM registry.
• Inclusion criteria: biopsy-proven GCM, survival >1 year post-diagnosis without heart transplantation.
• Data collected: death, heart transplantation, ventricular assist device (VAD) placement, disease recurrence, heart failure, arrhythmias, renal failure, and infections.

Main Results:

• The cohort (n=26) had a mean follow-up of 5.5 years post-initial year. Outcomes included 12% deaths, 19% heart transplants, and 4% VAD placement.
• GCM recurrence occurred in 12% of patients up to 8 years post-diagnosis. Heart failure episodes were frequent (30 episodes in 13 patients).
• Significant rates of renal failure (23 episodes) and infections (41 events) were observed. Combined adverse event rate (death, transplant, VAD, recurrence) was 47% at 5 years post-diagnosis.

Conclusions:

• GCM patients surviving the first year without transplantation face ongoing risks of recurrence, heart failure, and other complications.
• The risk of GCM recurrence extends to at least 8 years after initial diagnosis, necessitating prolonged clinical surveillance.